Irritable bowel syndrome, a prevalent functional bowel disorder, significantly affects patients' everyday lives and imposes a substantial economic burden on society. However, treatments options for managing diarrhea-predominant irritable bowel syndrome are limited. Rifaximin along with metronidazole is proposed as a treatment option for irritable bowel syndrome with diarrhea. The aim of this study was to evaluate the efficacy and tolerability of a fixed dose combination of rifaximin and metronidazole in the management of irritable bowel syndrome with diarrhea. An open-label, non-comparative, non- randomized, multicentre trial was conducted in 25 subjects presenting with acute diarrheal episodes associated with irritable bowel syndrome. The study was approved by institutional research ethics committee and participants provided signed informed consent. Patients were given fixed dose combination tablet containing rifaximin 200mg and metronidazole 400mg twice daily for 5 days.

Acute diarrhea is a frequent illness in children, especially in developing nations, posing risks of dehydration, malnutrition, and even death. Recently, there's been rising interest in Rifaximin and Metronidazole Fixed Dose Combination (FDC) as a treatment option for pediatric acute diarrhea. The aim of this study was to evaluate the efficiency and tolerability of rifaximin and metronidazole fixed-dose combination in the management of acute diarrhea in children. This was a multicenter, open-label, non- comparative, and non-randomized trial that enrolled 80 patients (age <18 years) experiencing acute diarrhea caused by various factors. This observational study was conducted post-approval of drugs by state Food and Drug Administration (FDA), therefore informed consent and ethics approval were not mandatory. Patients received suspension containing 100mg rifaximin and 200mg metronidazole per 5ml, twice daily for 5 days based on body weight. The primary endpoint assessed was change in frequency of loose/watery stools, fever, nausea, vomiting, abdominal pain, and gas/flatus from baseline to day 5.

Neuropathic pain presents significant clinical challenges due to its complex pathophysiology and varied patient response to treatment. While multiple pharmacologic options are available, healthcare provider’s preferences and prescribing behaviors can influence treatment outcomes and patient adherence. This study aimed to evaluate the preferences of healthcare providers in India and their current prescription trends in the management of neuropathic pain. A cross-sectional survey was conducted among 755 practicing healthcare professionals across India, comprising 376 orthopedic specialists and 379 physicians. A structured questionnaire was used to assess preferred drug molecule from tricyclic antidepressant class, factors affecting drug selection (e.g., perceived efficacy, patient tolerability, cost), preferred combination and prescribing trends of Nortriptyline, Pregabalin and Mecobalamin (NPM) combination. Descriptive statistics were used to analyze the responses. Nortriptyline was the most preferred tricyclic antidepressant for neuropathic pain (40.98%), followed by amitriptyline (33.26%) and protriptyline (15.66%.

Diabetes Mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both. DM is a significant health care concern. Worldwide, the prevalence is increasing at an alarming rate despite using different classes of anti-hyperglycemic agents. Although several treatment options reduce hyperglycemia, only half the patients achieve desirable glycemic targets. Newer treatments that significantly reduce hyperglycemia with novel mechanism of action and acceptable safety profiles are warranted to reduce complications associated with type 2 DM. Sodium-glucose cotransporter-2 inhibitors are anti-hyperglycemic agents with unique mechanism of action that lower blood glucose level independent of insulin. Recent findings on efficacy and safety establish their role in the treatment of DM. Sodium-glucose cotransporter-2 inhibitors may be an option in type 2 DM patients not willing or not ready to start insulin, those requiring additional glucose lowering and in those with acceptable risk factor profiles. Dapagliflozin (Farxiga) can be used at any stage of type 2 DM as a mono-therapy or in combination with other oral hypoglycemic agents and insulin. This review highlights the efficacy and safety of dapagliflozin as an anti-hyperglycemic agent and its use in co-morbid conditions like chronic kidney disease and cardiovascular diseases

To evaluate the efficacy and tolerability of fixed dose combination of curcumin and piperine in osteoarthritis (OA), a non-randomized, open labeled, non-comparative, single-centric, and post marketing surveillance (PMS) study was conducted in 166 osteoarthritic patients (73 men and 93 women, mean age: 54.5 ± 12.45 years). Each patient was administered a combination of curcumin 500 mg and piperine 5 mg twice daily for 12 weeks. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used as a tool to assess the efficacy of the fixe dose combination during the 12 weeks therapy. At the end of 12 weeks of therapy, WOMAC score improved significantly (p<0.0001) from 65.82 ± 18.10 to 25.12 ± 21.26. Also a significant reduction (p<0.0001) was found in scores for pain, stiffness and physical function from 15.03 ± 3.74 to 5.83 ± 4.42, 5.43 ± 1.95 to 1.52 ± 1.56 and 45.57 ± 13.72 to 17.76 ± 16.23 respectively at the end of 12 weeks. Combination of Curcumin and Piperine was effective and safe for the management of osteoarthritis in Indian patients.

Present study evaluates efficacy and tolerability of fixed dose combination of Voglibose and Repaglinide in postprandial hyperglycemia (PPHG).A non-randomized, open labeled, non-comparative, multi-centric, study was conducted in 69 Type 2 diabetes mellitus (T2DM) patients, 53 (76.8%) men and 16 (23.2%) women. Each patient was administered a fixed dose combination of voglibose 0.3mg and repaglinide 1mg twice a day, just before each meal for 90 days. Fasting blood glucose (FBG) and postprandial blood glucose (PPBG) levels were measured at baseline (day zero), on day 30 and on day 90. Glycated Haemoglobin (HbA1c) was measured at baseline and on day 90. There was significant reduction in PPBG (31.2%), FBG (31.6%), and HbA1c (10.3%) on day 90 compared to baseline. Therefore fixed dose combination of voglibose 0.3mg and repaglinide 1mg has a considerable impact on PPBG control. This combination was found to be efficacious in controlling PPHG and no cases of hypoglycemia were reported.